眾中文攝護腺癌專業系列-4：『轉移性荷爾蒙敏感性攝護腺癌』的最新治療 (翻譯NCCN攝護腺癌指南2023第一版)

蔣智宏^1,2、洪健華²、黃昭淵²

¹臺北榮民總醫院員山分院 泌尿外科

²臺灣大學附設醫院 泌尿部

Public Chinese Prostate Cancer Professional Series-3：Updated Treatment for metastatic Castration-Sensitive Prostate Cancer (mCSPC) (translated from NCCN Prostate Cancer Guidelines 2023 V1)

Chih-Hung Chiang^1,2、Jian‑Hua Hong²、Chao‑Yuan Huang²

¹ Department of Urology, Taipei Veterans General Hospital, Yuan-Shan Branch；

² Departments of Urology, National Taiwan University Hospital

Purpose：There are few specialized Chinese series on prostate cancer (PCa). This article is completely translated into Chinese according to the NCCN PCa Guideline Version 1. 2023. It is hoped that through the clear and easy-to-understand professional Chinese PCa series introduction, patients and their families can get the most correct and complete understanding from accurate biopsy diagnosis to the latest PCa treatment methods.

Materials and Methods：This section, Updated Treatment for metastatic Castration-Sensitive Prostate Cancer (mCSPC), is translated from the NCCN PCa Guidelines Versions 1. 2023.

Results：Androgen Deprivation Therapy (ADT) to maintain castration level of testosterone <50 ng/dL is the essential treatment for mCSPC. In addition, the addition of Abiraterone or Apalutamide or Enzalutamide is also one of the recommended treatment combinations for mCSPC. Additional radiation therapy to the prostate prolong overall survival and reduce the risk of death in “low volume” mCSPC patients. Triple Therapy is a new breakthrough in (high volume) mCSPC treatment in 2022：ADT + 6 cycle Docetaxel chemotherapy($) + Abiraterone($) or Darolutamide($) can significantly prolong overall survival and reduce the risk of death.

Conclusion：Objective detailed clinical evaluation and adequate communication are the key to the treatment selection of "metastatic Castration-Sensitive PCa".